https://rheumatologydigest.org/categories/guidelines/Recent content in Guidelines on Rheumatology DigestHugoen-usSat, 06 Jun 2026 13:00:00 +0100https://rheumatologydigest.org/posts/eular-2025-behcets-syndrome/Sat, 06 Jun 2026 13:00:00 +0100https://rheumatologydigest.org/posts/eular-2025-behcets-syndrome/The 2025 EULAR update to the Behçet’s syndrome recommendations moves monoclonal TNF-alpha inhibitors (especially infliximab) to first-line induction and maintenance for eye, vascular and parenchymal-CNS disease, displacing cyclophosphamide and the azathioprine-first strategy, and broadens treatment targets to angiographic and endoscopic remission.https://rheumatologydigest.org/posts/eular-2025-ra-management/Fri, 05 Jun 2026 13:00:00 +0100https://rheumatologydigest.org/posts/eular-2025-ra-management/The 2025 EULAR update streamlines RA management to 5 overarching principles and 9 recommendations, abandons post-methotrexate prognostic risk stratification, and keeps JAK inhibitors co-equal with biologics after individual risk assessment.